2014-31: Hydroxychloroquine in the treatment of chronic recurrent HLA-B27 associated uveitis
Hydroxychloroquine (HCQ) is a 4-aminoquinoline antimalarial drug that is widely used as a non-steroidal immunomodulating agent in patients with various autoimmune diseases, particularly systemic lupus erythematosus and rheumatoid arthritis. The immunosuppressive properties of HCQ relate, in part, to its interference with normal antigen processing and presentation. HCQ has also been shown to block proliferative responses to T-cell mitogens and alloantigens and to reduce the release of various cytokines, including interleukin (IL)-6 and tumor necrosis factor. However, the use of HCQ in non-infectious (HLA-B27 associated) uveitis to reduce the number and severity of recurrences is mostly empirical. In this retrospective case series, the effect of HCQ will be evaluated on the number and severity of recurrences and its sparing effect on additional topical or periocular steroids in HLA-B27 associated non-infectious uveitis.